Search Results

Deals

Eli Lilly and Company and Sigilon Therapeutics, Inc. announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.

June 29, 2023

·

10 min read

Deals

Lilly Completes Acquisition of Sigilon Therapeutics

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX).

August 14, 2023

·

5 min read

Deals

Sigilon Announces Reverse Stock Split of Common Stock

Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock.

May 22, 2023

·

4 min read

Pictured: Eli Lilly's biotechnology center in San Diego, California

Deals

Lilly to Buy Diabetes Cell Therapy Partner Sigilon for Just Over $300M

Eli Lilly announced Thursday it will acquire former collaborative partner Sigilon Therapeutics to deepen its diabetic foothold with a potentially functional cure for Type 1.

June 29, 2023

·

2 min read

·

Kate Goodwin

Genetown

Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference

Sigilon Therapeutics, Inc. today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Virtual Healthcare Conference.

April 18, 2023

·

1 min read

Business

Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Sigilon Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2023 as well as certain other business highlights.

May 9, 2023

·

10 min read

Business

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Sigilon Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 as well as certain other business highlights.

March 14, 2023

·

10 min read

Business

Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Sigilon Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 as well as certain other business highlights.

November 10, 2022

·

11 min read

Business

Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, reported financial results for the second quarter ended June 30, 2022 as well as certain other business highlights.

August 4, 2022

·

9 min read

Genetown

Sigilon Therapeutics to Present at the Needham Healthcare Conference

Sigilon Therapeutics, Inc. today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Healthcare Conference. The presentation will take place on Thursday, April 14, 2022 at 8:45 a.m. EDT.

April 7, 2022

·

1 min read